New hope for patients with Treatment-Resistant blood disorder
NCT ID NCT05676697
Summary
This early-stage study tested a drug called Linperlisib for adults with autoimmune hemolytic anemia (AIHA) whose disease returned or didn't improve after at least two standard treatments. The goal was to see if the drug could safely help control the disease by improving blood counts and reducing symptoms. Only four patients were enrolled in this small pilot trial before it was stopped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
-
Zhoukou Central Hospital
Zhoukou, Henan, China
Conditions
Explore the condition pages connected to this study.